The Journal of Pain
Volume 11, Issue 10 , Pages 972-982 , October 2010

A Multicenter, Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia

  • Lynn R. Webster

      Affiliations

    • Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah
    • Corresponding Author InformationAddress reprint requests to Lynn R. Webster, M.D., LifeTree Clinical Research, 3838 South 700 East, Suite 202, Salt Lake City, UT 84106.
    • ,
  • T. Philip Malan

      Affiliations

    • University of Arizona, Department of Anesthesiology, Tucson, Arizona
    • ,
  • Michael M. Tuchman

      Affiliations

    • Palm Beach Neurological Center, Palm Beach Gardens, Florida
    • ,
  • Martin D. Mollen

      Affiliations

    • Arizona Research Center, Phoenix, Arizona
    • ,
  • Jeffrey K. Tobias

      Affiliations

    • NeurogesX, Inc., San Mateo, California
    • ,
  • Geertrui F. Vanhove

      Affiliations

    • NeurogesX, Inc., San Mateo, California

Received 22 September 2009 ,Revised 21 December 2009 ,Accepted 15 January 2010.

References 

  1. Backonja MM, Dunteman E, Irving GA, Blonsky ER, Vanhove GF, Lu S-P, et al. One 60-minute application of a high-concentration capsaicin patch (NGX-4010) significantly reduced pain for up to 3 months in patients with postherpetic neuralgia: Results from a randomized, double-blind, controlled phase 3 study. Neurology. 2008;70(Suppl 1):A162–A163
  2. Backonja M, Irving G, Argoff C. Rational Multidrug Therapy in the Treatment of Neuropathic Pain. Curr Pain Headache Rep. 2006;10:34–38
  3. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–1112
  4. Baron R, Wasner G. Prevention and treatment of postherpetic neuralgia. Lancet. 2006;367:186–188
  5. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21:265–270
  6. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs. 2004;13:1445–1456
  7. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138
  8. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem. 2004;271:1814–1819
  9. Craft RM. Sex differences in opioid analgesia: ”from mouse to man”. Clin J Pain. 2003;19:175–186
  10. Dahan A, Kest B, Waxman AR, Sarton E. Sex-specific responses to opiates: animal and human studies. Anesth Analg. 2008;107:83–95
  11. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251
  12. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158
  13. Fillingim RB, Gear RW. Sex differences in opioid analgesia: clinical and experimental findings. Eur J Pain. 2004;8:413–425
  14. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10:447–485
  15. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305
  16. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: A descriptive study, 2002–2005. BMC Fam Pract. 2008;9:26
  17. Irving GA, Backonja MM, Blonsky ER, Rauck R, Gazda SK, Lu S-P, et al. NGX-4010, a high-concentration capsaicin patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. J Pain. 2009;10(Suppl 1):S57
  18. Jackson KC. II: Pharmacotherapy for neuropathic pain. Pain Pract. 2006;6:27–33
  19. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003;326:748–750
  20. Lauria G, Morbin M, Lombardi R, Capobianco R, Camozzi F, Pareyson D, et al. Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. J Peripher Nerv Syst. 2006;11:262–271
  21. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197
  22. Miaskowski C, Gear RW, Levine JD. Sex-related differences in analgesic responses. In:  Fillingim R editors. Sex, Gender and Pain. Seattle, WA: IASP Press; 2000;p. 209–230
  23. Peikert A, Hentrich M, Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol. 1991;238:452–456
  24. Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain. 2000;88:125–133
  25. Robinson ME, Riley JL, Brown FF, Gremillion H. Sex differences in response to cutaneous anesthesia: a double blind randomized study. Pain. 1998;77:143–149
  26. Rowbotham MC, Petersen KL. Zoster-associated pain and neural dysfunction. Pain. 2001;93:1–5
  27. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–354
  28. Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, et al. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006;20(Suppl 3):S124–S138
  29. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400
  30. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159–212
  31. Tominaga M. Nociception and TRP channels. Handb Exp Pharmacol. 2007;179:489–505
  32. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products. Washington, DC. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, 1999. Available at: http://www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf#search=%22HillTop%20Research%2C%20Inc.%20dermal%20irritation%22.
  33. Walker JS, Carmody JJ. Experimental pain in healthy human subjects: Gender differences in nociception and in response to ibuprofen. Anesth Analg. 1998;86:1257–1262
  34. Watson CP. A new treatment for postherpetic neuralgia. N Engl J Med. 2000;343:1563–1565

 Funding for this study was provided by NeurogesX.

PII: S1526-5900(10)00296-8

doi: 10.1016/j.jpain.2010.01.270

The Journal of Pain
Volume 11, Issue 10 , Pages 972-982 , October 2010

Article Tools

* Image Usage & Resolution